Jeffrey Ambroso is a senior scientist at RTI where he leads projects evaluating the safety and toxicology of drugs and environmental chemicals. He designs and conducts general and reproductive toxicology studies and authors nonclinical regulatory documents (IBs, INDs, preIND meeting briefing packages). Dr. Ambroso also specializes in troubleshooting and investigative toxicology study design and has experience in nonclinical safety evaluation and regulatory strategy for biological therapies.
Currently, Dr. Ambroso works on several toxicology related projects, including the Combating Antibiotic Resistance Bacteria (CARB-X), where he serves as a subject matter expert on multiple company support teams to provide strategic and regulatory consulting in nonclinical therapeutic development. Dr. Ambroso serves as a subject matter expert providing toxicology expertise for the Global Alliance for Tuberculosis Drug Development and other private drug development firms. He also leads a project for the EPA investigating the toxicology of poly- and perfluoroalkyl substances (PFAS) which will contribute to regulating these environmental contaminants.
Dr. Ambroso joined RTI in 2015 after 15 years of experience in nonclinical toxicology and drug safety at GlaxoSmithKline working on projects in all phases of development from discovery to marketing approval. He also has two years’ experience in commodity chemical toxicology and safety evaluation at Exxon Biomedical.
